Letter to the editor
Recent updates on daidzein against oxidative stress and cancer
Sarita Rawat1, Sachchidanand Pathak1, Gaurav Gupta1, Santosh Kumar Singh1, Himmat Singh1, Anurag Mishra1, Ritu Gilhotra1
1School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur, India
EXCLI J 2019;18:Doc950
Dear Editor,
Daidzein (7-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one) is a naturally occurring compound commonly found in soybeans and some other legumes. Daidzein is an isoflavone by nature and isolated from Pueraria Mirifica, having category of biologically active secondary metabolites commonly produced in the soybean growth and belong to the group of flavonoids. A number of pharmacological activities have been accounted for daidzein, which includes anti-carcinogenesis, anti-fibrotic, anti-diabetic, cholesterol-lowering and cardiovascular activity. Daidzein pretreatment was found to diminish the seriousness of mucosal damage in a portion subordinate way. Some other therapeutic uses of daidzein are weight reduction, decreasing bowels moment, and inflammation associated with histopathological deformities (Amaral et al., 2017[1]). Their structure and function are alike to human estrogen, which can play a massive role in the prevention of osteoporosis, cancer, and postmenopausal syndromes. Uses of daidzein in anticancer activity against ovarian cancer are still limited (Meng et al., 2017[14]). Epidemiological data suggest that increased utilization of soybean in food results in decreased cancer risk. Soybean food is highly recommended in cancer prevention because it has a number of anticarcinogens (Yu et al., 2017[23]). The potent antioxidant activity of daidzein reported in various in vitro and in vivo studies was conclusively shown in this literature (Table 1(Tab. 1); References in Table 1: Amaral et al., 2017[1]; Atiq et al., 2019[2]; Budryn et al., 2018[3]; Chan et al., 2018[4]; Davis et al., 2001[5]; Eskra et al., 2019[6]; Foti et al., 2005[7]; Gundogdu et al., 2018[8]; Hua et al., 2018[9]; Huang et al., 2019[10]; Karale and Kamath, 2017[11]; Liang et al., 2018[12]; Medeiros et al., 2016[13]; Meng et al., 2017[14]; Murata et al., 2004[15]; Park et al., 2016[16]; Poschner et al., 2017[17]; Rigalli et al., 2019[18]; Rohrdanz et al., 2002[19]; Sivoňová et al., 2019[20]; Uifalean et al., 2018[21]; Wei et al., 2019[22]; Zheng et al., 2017[25]; Zheng et al., 2018[24]; Zhu et al., 2018[26]).
Conflict of interest
The authors declare no conflict of interest.
References
1.
Amaral C, Toloi MRT, Vasconcelos LD, Fonseca MJV, Correia-da-Silva G, Teixeira N. The role of soybean extracts and isoflavones in hormone-dependent breast cancer: Aromatase activity and biological effects. Food Funct. 2017;8:3064-74.2.
Atiq A, Shal B, Naveed M, Khan A, Ali J, Zeeshan S, et al. Daidzein ameliorates 5-fluorouracil-induced intestinal mucositis by suppressing oxidative stress and inflammatory mediators in rodents. Eur J Pharmacol. 2019;843:292-306.3.
Budryn G, Grzelczyk J, Pérez-Sánchez H. Binding of red clover isoflavones to actin as a potential mechanism of anti-metastatic activity restricting the migration of cancer cells. Molecules. 2018;23:E2471.4.
Chan KKL, Siu MKY, Jiang YX, Wang JJ, Leung THY, Ngan HYS. Estrogen receptor modulators genistein, daidzein and erb-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of fak and pi3k/akt signaling in ovarian cancer. Cancer Cell Int. 2018;18:65.5.
Davis JN, Kucuk O, Djuric Z, Sarkar FH. Soy isoflavone supplementation in healthy men prevents nf-kappa b activation by tnf-alpha in blood lymphocytes. Free Radic Biol Med. 2001;30:1293-302.6.
Eskra JN, Schlicht MJ, Bosland MC. Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer. The Prostate. 2019;79:223-33.7.
Foti P, Erba D, Riso P, Spadafranca A, Criscuoli F, Testolin G. Comparison between daidzein and genistein antioxidant activity in primary and cancer lymphocytes. Arch Biochem Biophys. 2005;433:421-7.8.
Gundogdu G, Dodurga Y, Cetin M, Secme M, Cicek B. The cytotoxic and genotoxic effects of daidzein on mia paca-2 human pancreatic carcinoma cells and ht-29 human colon cancer cells. Drug Chem Toxicol. 2018;1-7;epub ahead of print.9.
Hua F, Li CH, Chen XG, Liu XP. Daidzein exerts anticancer activity towards skov3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the raf/mek/erk cascade. Int J Mol Med. 2018;41:3485-92.10.
Huang G, Xu J, Guo TL. Isoflavone daidzein regulates immune responses in the b6c3f1 and non-obese diabetic (nod) mice. Int Immunopharmacol. 2019;71:277-84.11.
Karale S, Kamath JV. Effect of daidzein on cisplatin-induced hematotoxicity and hepatotoxicity in experimental rats. Indian J Pharmacol. 2017;49:49-54.12.
Liang YS, Qi WT, Guo W, Wang CL, Hu ZB, Li AK. Genistein and daidzein induce apoptosis of colon cancer cells by inhibiting the accumulation of lipid droplets. Food Nutr Res. 2018;62:10.29219/fnr.v62.1384. 13.
Medeiros PS, Batista de Carvalho AL, Ruano C, Otero JC, Marques MP. Raman microspectroscopy for probing the impact of a dietary antioxidant on human breast cancer cells. Food Funct. 2016;7:2800-10.14.
Meng H, Fu G, Shen J, Shen K, Xu Z, Wang Y, et al. Ameliorative effect of daidzein on cisplatin-induced nephrotoxicity in mice via modulation of inflammation, oxidative stress, and cell death. Oxid Med Cell Longev. 2017;2017:3140680.15.
Murata M, Midorikawa K, Koh M, Umezawa K, Kawanishi S. Genistein and daidzein induce cell proliferation and their metabolites cause oxidative DNA damage in relation to isoflavone-induced cancer of estrogen-sensitive organs. Biochemistry. 2004;43:2569-77.16.
Park MH, Ju JW, Kim M, Han JS. The protective effect of daidzein on high glucose-induced oxidative stress in human umbilical vein endothelial cells. Z Naturforsch C J Biosci. 2016;71(1-2):21-8.17.
Poschner S, Maier-Salamon A, Zehl M, Wackerlig J, Dobusch D, Pachmann B, et al. The impacts of genistein and daidzein on estrogen conjugations in human breast cancer cells: A targeted metabolomics approach. Front Pharmacol. 2017;8:699.18.
Rigalli JP, Scholz PN, Tocchetti GN, Ruiz ML, Weiss J. The phytoestrogens daidzein and equol inhibit the drug transporter bcrp/abcg2 in breast cancer cells: Potential chemosensitizing effect. Eur J Nutr. 2019;58:139-50.19.
Rohrdanz E, Ohler S, Tran-Thi QH, Kahl R. The phytoestrogen daidzein affects the antioxidant enzyme system of rat hepatoma h4iie cells. J Nutr. 2002;132:370-5.20.
Sivoňová MK, Kaplán P, Tatarková Z, Lichardusová L, Dušenka R, Jurečeková J. Androgen receptor and soy isoflavones in prostate cancer. Mol Clin Oncol. 2019;10:191-204.21.
Uifalean A, Rath H, Hammer E, Ionescu C, Iuga CA, Lalk M. Influence of soy isoflavones in breast cancer angiogenesis: A multiplex glass elisa approach. J BUON. 2018;23(7):53-9.22.
Wei J, Yang F, Gong C, Shi X, Wang G. Protective effect of daidzein against streptozotocin-induced alzheimer's disease via improving cognitive dysfunction and oxidative stress in rat model. J Biochem Mol Toxicol. 2019;33:e22319.23.
Yu B, Tang DZ, Li SY, Wu Y, Chen M. Daidzein promotes proliferation and differentiation in osteoblastic oct1 cells via activation of the bmp-2/smads pathway. Pharmazie. 2017;72(1):35-40.24.
Zheng W, Liu T, Sun R, Yang L, An R, Xue Y. Daidzein induces choriocarcinoma cell apoptosis in a dose-dependent manner via the mitochondrial apoptotic pathway. Mol Med Rep. 2018;17:6093-9.25.
Zheng W, Sun R, Yang L, Zeng X, Xue Y, An R. Daidzein inhibits choriocarcinoma proliferation by arresting cell cycle at g1 phase through suppressing erk pathway in vitro and in vivo. Oncol Rep. 2017;38:2518-24.26.
Zhu Y, Yao Y, Shi Z, Everaert N, Ren G. Synergistic effect of bioactive anticarcinogens from soybean on anti-proliferative activity in mda-mb-231 and mcf-7 human breast cancer cells in vitro. Molecules. 2018;23(7):E1557.
Table 1: Recent updates on daidzein against oxidative stress and cancer